Am J Psychiatry 157:514-520, April 2000
© 2000 American Psychiatric Association
Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia
Shitij Kapur, M.D., Ph.D., F.R.C.P.C.,
Robert Zipursky, M.D., F.R.C.P.C.,
Corey Jones, B.A.,
Gary Remington, M.D., Ph.D., F.R.C.P.C., and
Sylvain Houle, M.D., Ph.D., F.R.C.P.C.
OBJECTIVE: Since all antipsychotics block dopamine D2 receptors, the authors investigated how well D2 receptor occupancy in vivo predicts clinical response, extrapyramidal side effects, and hyperprolactinemia. METHOD: In a double-blind study, 22 patients with first-episode schizophrenia were randomly assigned to 1.0 or 2.5 mg/day of haloperidol. After 2 weeks of treatment, D2 receptor occupancy was determined with [11C]raclopride and positron emission tomography, and clinical response, extrapyramidal side effects, and prolactin levels were measured. Patients who showed adequate responses continued taking their initial doses, those who did not respond had their doses increased to 5.0 mg/day, and evaluations were repeated at 4 weeks for all patients. RESULTS: The patients showed a wide range of D2 occupancy (38%–87%). The degree of receptor occupancy predicted clinical improvement, hyperprolactinemia, and extrapyramidal side effects. The likelihood of clinical response, hyperprolactinemia, and extrapyramidal side effects increased significantly as D2 occupancy exceeded 65%, 72%, and 78%, respectively. CONCLUSIONS: The study confirms that D2 occupancy is an important mediator of response and side effects in antipsychotic treatment. The data are consistent with a "target and trigger" hypothesis of antipsychotic action, i.e., that the D2 receptor specificity of antipsychotics permits them to target discrete neurons and that their antagonist properties trigger within those neurons intracellular changes that ultimately beget antipsychotic response. While limited to haloperidol, the relationship between D2 occupancy and side effects in this study helps explain many of the observed clinical differences between typical and atypical antipsychotics.
This article has been cited by other articles:
|
|
|
|
 
C. Dolder, M. Nelson, and Z. Deyo
Paliperidone for schizophrenia
Am. J. Health Syst. Pharm.,
March 1, 2008;
65(5):
403 - 413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fitzgerald and T. G Dinan
Prolactin and dopamine: What is the connection? A Review Article
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
12 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky
Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature
Schizophr Bull,
February 26, 2008;
(2008)
sbn009v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumra, J. V. Oberstar, L. Sikich, R. L. Findling, J. M. McClellan, S. Vinogradov, and S. Charles Schulz
Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
Schizophr Bull,
January 1, 2008;
34(1):
60 - 71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-N. Samaha, P. Seeman, J. Stewart, H. Rajabi, and S. Kapur
"Breakthrough" Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time
J. Neurosci.,
March 14, 2007;
27(11):
2979 - 2986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Masand
Differential pharmacology of atypical antipsychotics: Clinical implications
Am. J. Health Syst. Pharm.,
January 15, 2007;
64(2_Supplement_1):
S3 - S8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. McCUE, R. WAHEED, L. URCUYO, G. ORENDAIN, M. D. JOSEPH, R. CHARLES, and S. M. HASAN
Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia
The British Journal of Psychiatry,
November 1, 2006;
189(5):
433 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Meyer, H. E. McNeely, S. Sagrati, A. Boovariwala, K. Martin, N. P. L.G. Verhoeff, A. A. Wilson, and S. Houle
Elevated Putamen D2 Receptor Binding Potential in Major Depression With Motor Retardation: An [11C]Raclopride Positron Emission Tomography Study
Am J Psychiatry,
September 1, 2006;
163(9):
1594 - 1602.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur
A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone
Am J Psychiatry,
March 1, 2006;
163(3):
396 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ezewuzie and D. Taylor
Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia
J Psychopharmacol,
January 1, 2006;
20(1):
86 - 90.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. de HAAN, J. LAVALAYE, J. BOOIJ, and D. LINSZEN
Comfort, Self-Confidence, Safety, and Dopamine D2 Receptor Occupancy by Antipsychotics
Am J Psychiatry,
August 1, 2005;
162(8):
1544 - 1545.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. de HAAN and N. van BEVEREN
Olanzapine and Haloperidol for Residual Symptoms
Am J Psychiatry,
July 1, 2005;
162(7):
1392 - 1393.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Gardner, R. J. Baldessarini, and P. Waraich
Modern antipsychotic drugs: a critical overview
Can. Med. Assoc. J.,
June 21, 2005;
172(13):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Kippin, S. Kapur, and D. van der Kooy
Dopamine Specifically Inhibits Forebrain Neural Stem Cell Proliferation, Suggesting a Novel Effect of Antipsychotic Drugs
J. Neurosci.,
June 15, 2005;
25(24):
5815 - 5823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Woolley and P. McGuire
Neuroimaging in schizophrenia: what does it tell the clinician?
Advan. Psychiatr. Treat.,
May 1, 2005;
11(3):
195 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Bolonna and R. W. Kerwin
Partial agonism and schizophrenia
The British Journal of Psychiatry,
January 1, 2005;
186(1):
7 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Harvey, D. Flockhart, J. C. Gorski, D. J. Greenblatt, M. Burke, S. Werder, and S. H. Preskorn
Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia
J. Clin. Pharmacol.,
October 1, 2004;
44(10):
1173 - 1184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tauscher, T. Hussain, O. Agid, N. P. L.G. Verhoeff, A. A. Wilson, S. Houle, G. Remington, R. B. Zipursky, and S. Kapur
Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics
Am J Psychiatry,
September 1, 2004;
161(9):
1620 - 1625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al.
Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine
J Psychopharmacol,
September 1, 2004;
18(3):
355 - 365.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. M. Meaney, S. Smith, O. D. Howes, M. O'brien, R. M. Murray, and V. O'keane
Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia
The British Journal of Psychiatry,
June 1, 2004;
184(6):
503 - 508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Vreeland and E. Kim
Managing the Clinical Consequences of Psychiatric Illness and Antipsychotic Treatment: A Discussion of Obesity, Diabetes, and Hyperprolactinemia
Journal of the American Psychiatric Nurses Association,
June 1, 2004;
10(3_suppl):
S17 - S24.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Mamo, S. Kapur, C. M. Shammi, G. Papatheodorou, S. Mann, F. Therrien, and G. Remington
A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone
Am J Psychiatry,
May 1, 2004;
161(5):
818 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Meyer, A. A. Wilson, S. Sagrati, D. Hussey, A. Carella, W. Z. Potter, N. Ginovart, E. P. Spencer, A. Cheok, and S. Houle
Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study
Am J Psychiatry,
May 1, 2004;
161(5):
826 - 835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Grunder, A. Carlsson, and D. F. Wong
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Arch Gen Psychiatry,
October 1, 2003;
60(10):
974 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Bressan, K. Erlandsson, H. M. Jones, R. Mulligan, R. J. Flanagan, P. J. Ell, and L. S. Pilowsky
Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients
Am J Psychiatry,
August 1, 2003;
160(8):
1413 - 1420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur, S. C. VanderSpek, B. A. Brownlee, and J. N. Nobrega
Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy
J. Pharmacol. Exp. Ther.,
May 1, 2003;
305(2):
625 - 631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Pelton, D. P. Devanand, K. Bell, K. Marder, K. Marston, X. Liu, and T. B. Cooper
Usefulness of Plasma Haloperidol Levels for Monitoring Clinical Efficacy and Side Effects in Alzheimer Patients With Psychosis and Behavioral Dyscontrol
Am J Geriatr Psychiatry,
April 1, 2003;
11(2):
186 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. de Haan, M. van Bruggen, J. Lavalaye, J. Booij, P. M.A.J. Dingemans, and D. Linszen
Subjective Experience and D2 Receptor Occupancy in Patients With Recent-Onset Schizophrenia Treated With Low-Dose Olanzapine or Haloperidol: A Randomized, Double-Blind Study
Am J Psychiatry,
February 1, 2003;
160(2):
303 - 309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur
Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia
Am J Psychiatry,
January 1, 2003;
160(1):
13 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Taylor
Antipsychotic prescribing -- time to review practice
Psychiatr. Bull.,
November 1, 2002;
26(11):
401 - 402.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. JONES and L. S. PILOWSKY
Dopamine and antipsychotic drug action revisited
The British Journal of Psychiatry,
October 1, 2002;
181(4):
271 - 275.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur, X. Langlois, P. Vinken, A. A. H. P. Megens, R. De Coster, and J. S. Andrews
The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats
J. Pharmacol. Exp. Ther.,
September 1, 2002;
302(3):
1129 - 1134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Boyd
Atypical Antipsychotics: Impact on Overall Health and Quality of Life
Journal of the American Psychiatric Nurses Association,
August 1, 2002;
8(4_suppl):
S9 - S17.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. F. B. McTAVISH, M. H. McPHERSON, C. J. HARMER, L. CLARK, T. SHARP, G. M. GOODWIN, and P. J. COWEN
Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness
The British Journal of Psychiatry,
October 1, 2001;
179(4):
356 - 360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Oosthuizen, R. A. Emsley, and J. Turner
Low dose typical antipsychotics -- a brief evaluationAuthor's reply
Psychiatr. Bull.,
May 1, 2001;
25(5):
194 - 194.
[Full Text]
|
|
|
|
|
|
|
D. J. Lang, L. C. Kopala, R. A. Vandorpe, Q. Rui, G. N. Smith, V. M. Goghari, and W. G. Honer
An MRI Study of Basal Ganglia Volumes in First-Episode Schizophrenia Patients Treated With Risperidone
Am J Psychiatry,
April 1, 2001;
158(4):
625 - 631.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Kapur and P. Seeman
Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Am J Psychiatry,
March 1, 2001;
158(3):
360 - 369.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. G. Strange
Antipsychotic Drugs: Importance of Dopamine Receptors for Mechanisms of Therapeutic Actions and Side Effects
Pharmacol. Rev.,
March 1, 2001;
53(1):
119 - 134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur, P. Roy, J. Daskalakis, G. Remington, and R. Zipursky
Increased Dopamine D2 Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to Clozapine
Am J Psychiatry,
February 1, 2001;
158(2):
311 - 314.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Mossman and D. S. Lehrer
Conventional and Atypical Antipsychotics and the Evolving Standard of Care
Psychiatr Serv,
December 1, 2000;
51(12):
1528 - 1535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Millan
Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
J. Pharmacol. Exp. Ther.,
December 1, 2000;
295(3):
853 - 861.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Kapur, R. Zipursky, C. Jones, C. S. Shammi, G. Remington, and P. Seeman
A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy
Arch Gen Psychiatry,
June 1, 2000;
57(6):
553 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2000
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
